Oramed Pharmaceuticals Dividends
| ORMP Stock | USD 3.37 0.05 1.46% |
As of 02/01/2026, Dividend Paid And Capex Coverage Ratio is likely to drop to -441.65. Oramed Pharmaceuticals' past performance could be the main factor of why investors trade Oramed Pharmaceuticals stock today. Investors should clearly understand every aspect of the Oramed Pharmaceuticals dividend schedule, including its future sustainability, and how it might impact an overall investment strategy. This tool is helpful to digest Oramed Pharmaceuticals' dividend schedule and payout information. Oramed Pharmaceuticals dividends can also provide a clue to the current valuation of Oramed Pharmaceuticals.
| Last Reported | Projected for Next Year | ||
| Dividend Paid And Capex Coverage Ratio | (420.62) | (441.65) |
Investing in stocks that pay dividends is one of many strategies that are good for long-term investments. Ex-dividend dates are significant because investors in Oramed Pharmaceuticals must own a stock before its ex-dividend date to receive its next dividend.
Oramed Pharmaceuticals Expected Dividend Income Per Share
Dividend payment represents part of Oramed Pharmaceuticals' profit that is distributed to its stockholders. It is considered income for that tax year rather than a capital gain. In other words, a dividend is a prize given to shareholders for investing in Oramed Pharmaceuticals. Oramed Pharmaceuticals' board of directors can pay out dividends at a planned frequency, such as monthly or quarterly.
$0.08 |
One Year
Oramed Pharmaceuticals expected dividend income per share adjusted for ongoing price standard deviation
Oramed Pharmaceuticals Past Distributions to stockholders
Can Pharmaceuticals industry sustain growth momentum? Does Oramed have expansion opportunities? Factors like these will boost the valuation of Oramed Pharmaceuticals. Anticipated expansion of Oramed directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Oramed Pharmaceuticals demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Quarterly Earnings Growth 0.409 | Earnings Share 1 | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets |
Oramed Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Oramed's balance sheet. Smart investors calculate Oramed Pharmaceuticals' intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Oramed Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Oramed Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Oramed Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Oramed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.